Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WATERTOWN, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel...
-
Westport, CT, Aug. 31, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing...
-
We turn scientists into designers. Automatically.FLORIANOPOLIS, Brazil, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Objective: to save long hours of work for Life Science Researchers by helping them create...
-
Westport, CT, Aug. 19, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal...
-
NEW YORK and PALMERSTON NORTH, New Zealand, Aug. 16, 2021 (GLOBE NEWSWIRE) -- BioLumic Inc. (“BioLumic”), a biotechnology company that develops photomorphogenic light signals for agriculture, today...
-
OTTAWA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Defining Moments Canada, a heritage and education organisation, is proud to enter into partnership with the Embassy of the Federal Republic of Germany in...
-
Positive interim results from Single Ascending Dose portion of Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 demonstrated degrader proof-of-mechanism Recently initiated dosing of healthy...
-
BOCA RATON, Fla., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Xeriant, Inc. (OTCQB: XERI), (“Xeriant” or “the Company”), an aerospace company focused on Advanced Air Mobility (AAM), the exciting transition to...
-
Myriad’s MyRisk® Hereditary Cancer test with RiskScore® provides a breast cancer risk assessment for all women not previously diagnosed with breast cancer, regardless of ancestryMyRisk with RiskScore...
-
WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small...